This study is comparing two chemotherapy treatment plans for children and young adults with newly diagnosed intermediate risk rhabdomyosarcoma. Researchers want to learn whether a higher dose treatment given over a shorter time works as well as or better than a lower dose treatment with additional maintenance therapy given over a longer time, along with standard surgery and radiation.

Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Participants may be able to join if they are 50 years old or younger and have a newly diagnosed type of soft tissue cancer called rhabdomyosarcoma. They cannot have an uncontrolled infection or another cancer that is being treated with chemotherapy or radiation. People who had a different cancer treated only with surgery may still be eligible.

This study is comparing a higher dose chemotherapy treatment given over a shorter period of time with a lower dose chemotherapy treatment given over a longer period of time that includes maintenance therapy. Researchers want to learn which approach works better and understand the benefits and risks of each treatment for patients with intermediate risk rhabdomyosarcoma.